Heron launches APONVIE IV for PONV prevention; cites 50% fewer vomiting vs ondansetron

HERON THERAPEUTICS, INC. /DE/

APONVIE (aprepitant injectable emulsion) is first IV NK1 receptor antagonist for postoperative nausea and vomiting (PONV).
Single IV push achieves ≥97% brain receptor occupancy within 5 minutes and maintains therapeutic levels for 48 hours.
Aprepitant reduced vomiting by ~50% in first 24 and 48 hours vs IV ondansetron in clinical trials.
Target market: ~36 million U.S. procedures annually in high/moderate PONV risk patients; CEO sees potential for several hundred million dollars in sales.
Launch leverages existing acute-care commercial team with no additional field force or significant external spend.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.